Variations in body mass impose constraints on the structure and function of mammalian species, including those of the cardiovascular system. Numerous biological processes, including cardiovascular parameters, have been shown to scale with body mass (BM) according to the law of allometric scaling: Y=Y =a∙BM (Y, biological process; a, normalization constant; b, scaling exponent, which in many instances is a multiple of ¼). These parameters include heart and breathing rates, intervals and subintervals of the electrocardiogram (ECG), action potential duration (APD), metabolic rate, and temporal properties of ventricular fibrillation. For instance, the hierarchical branching networks of the vascular system, and of the specialized conduction system in the heart have been proposed to be important determinants of allometric scaling. A global and unifying molecular mechanism of allometric scaling has not been put forth, but changes in gene expression have been proposed to play an important role. Even though it is accepted that differences in body size have cardiovascular effects, the use of scaling in the clinical setting is limited. An increase in the clinical utilization of scaling is thought to lead to improved cardiovascular disease diagnosis and management in patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476364 | PMC |
http://dx.doi.org/10.1016/j.jtbi.2016.09.024 | DOI Listing |
Epilepsia
January 2025
Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Objective: Identifying factors influencing cannabidiol (CBD) exposure can optimize treatment efficacy and safety. We aimed to describe the population pharmacokinetics of CBD in children with drug-resistant developmental and epileptic encephalopathies (DEEs) and assess the influence of environmental, pharmacological, and clinical characteristics on CBD systemic exposure.
Methods: Data from two pharmacokinetic studies of patients aged 2-18 years with DEEs were included (N = 48 patients).
Plants (Basel)
December 2024
Co-Innovation Center for Sustainable Forestry in Southern China, Bamboo Research Institute, Nanjing Forestry University, #159 Longpan Road, Nanjing 210037, China.
Total leaf area per shoot () can reflect the photosynthetic capacity of a shoot. A prior study hypothesized that is proportional to the product of the sum of the individual leaf widths per shoot () and the maximum individual leaf length per shoot (), referred to as the Montgomery-Koyama-Smith equation (MKSE). However, empirical evidence does not support such a proportional relationship hypothesis, as was found to allometrically scale with , i.
View Article and Find Full Text PDFPharmaceutics
December 2024
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
SPT-07A, a D-borneol, is currently being developed in China for the treatment of ischemic stroke. We aimed to create a whole-body physiologically-based pharmacokinetic (PBPK) model to predict the pharmacokinetics of SPT-07A in rats, dogs, and humans. The in vitro metabolism of SPT-07A was studied using hepatic, renal, and intestinal microsomes.
View Article and Find Full Text PDFPlant Cell Environ
December 2024
CAS Key Laboratory of Forest Ecology and Silviculture, Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang, China.
Corner's rules are well known in describing inter-specific scaling relationships for plant organ size-related traits, from species with thick terminal stems, large leaves, and sparsely branched twigs to species with opposite traits; however, the implications of organ size on physiological functions and growth performance of trees remain unclear. Moreover, whether Corner's rules spectra differ between tree species with simple and compound leaves is not known. Here, we measured key twig morphological traits, physiological characteristics, and radial growth rates of 27 simple- and 6 compound-leaved tree species in a common garden in Northeast China.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, Republic of Korea.
AST-001, a novel syrup formulation of L-serine, was developed for the treatment of autism spectrum disorders (ASD) in pediatric patients. This study aimed to establish a pharmacokinetic (PK)-pharmacodynamic (PD) model to elucidate the effect of AST-001 on adaptive behavior in children with ASD. Due to the absence of PK samples in pediatric patients, a previously published population PK model was used to link the PD model by applying an allometric scale to body weight.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!